Multiple sclerosis following treatment with a cannabinoid receptor-1 antagonist

B. W. van Oosten; J. Killestein; E. M H Mathus-Vliegen; C. H. Polman

doi:https://doi.org/10.1191/1352458504ms1044oa

Multiple sclerosis following treatment with a cannabinoid receptor-1 antagonist

B. W. van Oosten, J. Killestein, E. M H Mathus-Vliegen, C. H. Polman

Research output: Contribution to journal › Article › Academic › peer-review

30 Citations (Scopus)

Abstract

Laboratory research including animal models of human disease suggests that cannabinoids might have therapeutic potential in multiple sclerosis (MS). We have recently seen a 46-year-old woman who developed MS after starting treatment with a cannabinoid receptor antagonist for obesity. The occurrence of MS several months after starting a cannabinoid receptor antagonist suggests that the cannabinoid system might indeed be relevant to disease pathogenesis in MS.

Original language	English
Pages (from-to)	330-331
Number of pages	2
Journal	MULTIPLE SCLEROSIS
Volume	10
Issue number	3
DOIs	https://doi.org/10.1191/1352458504ms1044oa
Publication status	Published - 1 Jun 2004

Keywords

Appetite depressants
Cannabinoid receptor antagonist
Endogenous cannabinoids
Multiple sclerosis
Obesity

Access to Document

https://doi.org/10.1191/1352458504ms1044oa

Cite this

@article{f3bd857cc91f436fa57f1ee2a0e8751b,

title = "Multiple sclerosis following treatment with a cannabinoid receptor-1 antagonist",

abstract = "Laboratory research including animal models of human disease suggests that cannabinoids might have therapeutic potential in multiple sclerosis (MS). We have recently seen a 46-year-old woman who developed MS after starting treatment with a cannabinoid receptor antagonist for obesity. The occurrence of MS several months after starting a cannabinoid receptor antagonist suggests that the cannabinoid system might indeed be relevant to disease pathogenesis in MS.",

keywords = "Appetite depressants, Cannabinoid receptor antagonist, Endogenous cannabinoids, Multiple sclerosis, Obesity",

author = "{van Oosten}, {B. W.} and J. Killestein and Mathus-Vliegen, {E. M H} and Polman, {C. H.}",

year = "2004",

month = jun,

day = "1",

doi = "https://doi.org/10.1191/1352458504ms1044oa",

language = "English",

volume = "10",

pages = "330--331",

journal = "MULTIPLE SCLEROSIS",

issn = "1352-4585",

publisher = "SAGE Publications Ltd",

number = "3",

}

TY - JOUR

T1 - Multiple sclerosis following treatment with a cannabinoid receptor-1 antagonist

AU - van Oosten, B. W.

AU - Killestein, J.

AU - Mathus-Vliegen, E. M H

AU - Polman, C. H.

PY - 2004/6/1

Y1 - 2004/6/1

N2 - Laboratory research including animal models of human disease suggests that cannabinoids might have therapeutic potential in multiple sclerosis (MS). We have recently seen a 46-year-old woman who developed MS after starting treatment with a cannabinoid receptor antagonist for obesity. The occurrence of MS several months after starting a cannabinoid receptor antagonist suggests that the cannabinoid system might indeed be relevant to disease pathogenesis in MS.

AB - Laboratory research including animal models of human disease suggests that cannabinoids might have therapeutic potential in multiple sclerosis (MS). We have recently seen a 46-year-old woman who developed MS after starting treatment with a cannabinoid receptor antagonist for obesity. The occurrence of MS several months after starting a cannabinoid receptor antagonist suggests that the cannabinoid system might indeed be relevant to disease pathogenesis in MS.

KW - Appetite depressants

KW - Cannabinoid receptor antagonist

KW - Endogenous cannabinoids

KW - Multiple sclerosis

KW - Obesity

UR - http://www.scopus.com/inward/record.url?scp=3042637406&partnerID=8YFLogxK

U2 - https://doi.org/10.1191/1352458504ms1044oa

DO - https://doi.org/10.1191/1352458504ms1044oa

M3 - Article

C2 - 15222701

SN - 1352-4585

VL - 10

SP - 330

EP - 331

JO - MULTIPLE SCLEROSIS

JF - MULTIPLE SCLEROSIS

IS - 3

ER -

Multiple sclerosis following treatment with a cannabinoid receptor-1 antagonist

Abstract

Keywords

Access to Document

Other files and links

Cite this